glp 1 drugs and autoimmune disease GLP-1 Agonists in GLP-1 Obesity Drugs May Lower

Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

Indication Segment Insights and Analysis: Based on the indication, the GLP-1 Receptor Agonist market is segmented into type 2 diabetes, obesity, cardiovascular diseases, liver cirrhosis, Non-alcoholic fatty liver disease (NAFLD), and others

H.ToftA

After 12 to 18 months, some patients may even be able to stop the GLP-1 drug and use FIM programming for weight maintenance

And several studies suggest that exenatide increased expression levels of BDNF in AD mice hippocampus and cortex (141, 203, 204)